Tag:

Bristol-Myers Squibb

Latest Headlines

Latest Headlines

UPDATED: FDA OKs AstraZeneca's long-delayed diabetes drug dapagliflozin

The FDA has handed AstraZeneca a green light to begin marketing dapagliflozin, its long-delayed SGLT2 diabetes drug, which will now try to defy the steadily dwindling expectations of market analysts. The treatment--the first new FDA drug approval for 2014--will be sold as Farxiga.

Bristol-Myers bails out of 'Diabetes Inc.' in $4.1B sell-out to AstraZeneca

When Bristol-Myers Squibb got out of the diabetes development business a couple of months ago, the logical follow-up question was this: Will the company bag diabetes sales, too? The answer is yes.

AstraZeneca will pay up to $4.1B for Bristol's share of their diabetes pact

As Bristol-Myers Squibb backs away from diabetes development, AstraZeneca has stepped up to buy its partner's stake in the pair's joint venture, agreeing to hand over as much as $4.1 billion in a move that will add some promise to a thinning pipeline.

AstraZeneca, BMS pull Forxiga in Germany in snit over pricing

AstraZeneca and Bristol-Myers Squibb look to be feeling good about the future of their diabetes drug Forxiga. The drugmakers have yanked the diabetes treatment from the market in Germany because they couldn't get the reimbursement they wanted from medical insurers. The nose-thumbing move came the day after an FDA panel recommended the drug for approval in the U.S.

FDA panel smiles on Bristol-Myers, AstraZeneca's diabetes drug in do-over

Two years after a stinging rejection at the hands of the same committee, Bristol-Myers Squibb and AstraZeneca got a warmer reception for their diabetes drug dapagliflozin, winning a recommendation from an FDA advisory panel and brightening their odds of approval for the once-rebuffed therapy.

Bristol-Myers licenses a second-line HIV drug for cheap copies in poor nations

Bristol-Myers Squibb agreed to license its HIV fighter Reyataz (atazanavir) to the Medicines Patent Pool, which will allow generics makers to turn out cheaper copies for sale in poor countries.

FDA panel throws dirt on Bristol-Myers' orphan drug metreleptin

Bristol-Myers Squibb's rare disease treatment metreleptin isn't up to snuff for its desired indication, an FDA committee voted, but agency advisers believe the drug shows some promise in a small subset of patients, giving the drug giant some hope for approval.

AZ, Bristol-Myers hopeful on dapagliflozin second try, but FDA staff remains wary

AstraZeneca and Bristol-Myers Squibb are heading back to the FDA with the once-spurned dapagliflozin, claiming they've addressed the diabetes drug's cancer risks, but agency staff remains wary of the treatment's dangers.

UPDATED: FDA still unconvinced on once-rejected diabetes drug from Bristol-Myers, AstraZeneca

AstraZeneca and Bristol-Myers Squibb are heading back to the FDA with the once-spurned dapagliflozin, claiming they've addressed the diabetes drug's cancer risks, but agency staff remains wary of the novel treatment's dangers.

FDA raises safety, efficacy questions for Bristol-Myers' rare-disease drug metreleptin

Bristol-Myers Squibb will go into its Wednesday panel session for the lipodystrophy drug metreleptin with an agency review that offers a grudging concession on signs of efficacy for a subgroup of patients along with some serious questions about potential safety issues and a number of criticisms for the way the clinical trial program was designed and executed.